ASX:VTI

Stock Analysis Report

Visioneering Technologies

Executive Summary

Visioneering Technologies, Inc., a medical device company, engages in the design, manufacture, sale, and distribution of contact lenses in the United States.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Risks

  • Visioneering Technologies has significant price volatility in the past 3 months.
  • Visioneering Technologies is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Visioneering Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-7.5%

ASX:VTI

3.8%

AU Medical Equipment

1.9%

AU Market


1 Year Return

-72.8%

ASX:VTI

7.3%

AU Medical Equipment

2.3%

AU Market

VTI underperformed the Medical Equipment industry which returned 7.3% over the past year.

VTI underperformed the Market in Australia which returned 2.3% over the past year.


Share holder returns

VTIIndustryMarket
7 Day-7.5%3.8%1.9%
30 Day-18.3%-4.0%-4.2%
90 Day-16.9%8.1%1.2%
1 Year-72.8%-72.8%9.1%7.3%8.0%2.3%
3 Yearn/a40.8%34.4%32.9%15.6%
5 Yearn/a133.5%113.7%39.3%8.4%

Price Volatility Vs. Market

How volatile is Visioneering Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Visioneering Technologies undervalued based on future cash flows and its price relative to the stock market?

2.95x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Visioneering Technologies to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Visioneering Technologies to establish if it is available at substantial discount.


Price Based on Earnings

Visioneering Technologies is loss making, we can't compare its value to the AU Medical Equipment industry average.

Visioneering Technologies is loss making, we can't compare the value of its earnings to the Australia market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Visioneering Technologies, we can't assess if its growth is good value.


Price Based on Value of Assets

Visioneering Technologies is good value based on assets compared to the AU Medical Equipment industry average.


Next Steps

Future Growth

How is Visioneering Technologies expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

52.9%

Forecasted annual revenue growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Visioneering Technologies's revenue is expected to grow significantly at over 20% yearly.

Unable to determine if Visioneering Technologies is high growth as no earnings estimate data is available.

Visioneering Technologies's revenue growth is expected to exceed the Australia market average.

Unable to compare Visioneering Technologies's earnings growth to the Australia market average as no estimate data is available.

Unable to compare Visioneering Technologies's earnings growth to the low risk savings rate as no estimate data is available.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Visioneering Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Visioneering Technologies performed over the past 5 years?

-25.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Visioneering Technologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Visioneering Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Visioneering Technologies's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Visioneering Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Visioneering Technologies has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Visioneering Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Visioneering Technologies's financial position?


Financial Position Analysis

Visioneering Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Visioneering Technologies's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Visioneering Technologies has no debt.

Visioneering Technologies currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

High level of physical assets or inventory.

Visioneering Technologies has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Visioneering Technologies has less than a year of cash runway based on current free cash flow.

Visioneering Technologies has less than a year of cash runway if free cash flow continues to grow at historical rates of 24.8% each year.


Next Steps

Dividend

What is Visioneering Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Visioneering Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Visioneering Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Visioneering Technologies has not reported any payouts.

Unable to verify if Visioneering Technologies's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Visioneering Technologies has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Visioneering Technologies's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Stephen Snowdy (49yo)

6.2yrs

Tenure

0

Dr. Stephen Snowdy, Ph,D., has been Chief Executive Officer of Visioneering Technologies, Inc. June 2013 and serves as its President and Executive Director. Dr. Snowdy is a Principal at Memphis Biomed Vent ...


Management Age and Tenure

2.3yrs

Average Tenure

The tenure for the Visioneering Technologies management team is about average.


Board Age and Tenure

2.3yrs

Average Tenure

54yo

Average Age

The average tenure for the Visioneering Technologies board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by Visioneering Technologies individual insiders in the past 3 months.


Recent Insider Transactions

SellUS$792,61209 Jul 19
Regal Funds Management Pty Limited
EntityCompany
Shares15,132,697
Max PriceUS$0.059
BuyUS$527,68909 Jul 19
Regal Funds Management Pty Limited
EntityCompany
Shares9,772,245
Max PriceUS$0.054
BuyUS$809,19817 Jun 19
TIGA Trading Pty Ltd, Asset Management Arm
EntityCompany
Shares17,862,572
Max PriceUS$0.11
BuyUS$203,94017 Jun 19
Thorney Technologies Ltd
EntityCompany
Shares4,480,784
Max PriceUS$0.11
SellUS$151,08314 Jun 19
Regal Funds Management Pty Limited
EntityCompany
Shares2,427,833
Max PriceUS$0.064
BuyUS$1,929,92512 Jun 19
Paul Cozzi
EntityIndividual
Shares20,082,748
Max PriceUS$0.096
SellUS$218,38313 May 19
Regal Funds Management Pty Limited
EntityCompany
Shares2,364,325
Max PriceUS$0.092
BuyUS$2,07013 May 19
Regal Funds Management Pty Limited
EntityCompany
Shares30,000
Max PriceUS$0.069
SellUS$40,85116 Apr 19
Renaissance Smaller Companies Pty Ltd
EntityCompany
Shares524,548
Max PriceUS$0.078
BuyUS$299,99911 Apr 19
Renaissance Smaller Companies Pty Ltd
EntityCompany
Shares1,666,667
Max PriceUS$0.18
SellUS$136,60311 Apr 19
Renaissance Smaller Companies Pty Ltd
EntityCompany
Shares1,394,495
Max PriceUS$0.098
SellUS$53,67604 Apr 19
Kinetic Investment Partners Limited
EntityCompany
Shares808,755
Max PriceUS$0.066
SellUS$61,47706 Mar 19
Kinetic Investment Partners Limited
EntityCompany
Shares354,743
Max PriceUS$0.17
BuyUS$61,47706 Mar 19
Kinetic Investment Partners Limited
EntityCompany
Shares354,743
Max PriceUS$0.17
SellUS$496,64126 Feb 19
Regal Funds Management Pty Limited
EntityCompany
Shares3,313,767
Max PriceUS$0.15
BuyUS$15,00016 Sep 18
Zita Peach
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares83,333
Max PriceUS$0.18

Ownership Breakdown


Management Team

  • Brian Lane (57yo)

    Chief Financial Officer

    • Tenure: 0.7yrs
  • Stephen Snowdy (49yo)

    CEO, President & Executive Director

    • Tenure: 6.2yrs
  • Tony Sommer

    Senior Vice President of Sales & Marketing

    • Tenure: 2.9yrs
  • Julian Rockett

    Company Secretary

    • Tenure: 0.5yrs
  • Richard Griffin

    Founder & Medical Adviser

    • Tenure: 0.0yrs
  • Rosa Lee

    Executive Director of Manufacturing & Engineering

    • Tenure: 2.7yrs
  • Layna Mendlinger

    Executive Director of Marketing

    • Tenure: 0.0yrs
  • Sally Dillehay

    Chief Medical Officer

    • Tenure: 0.0yrs
  • Doug Benoit

    Executive Director of Professional Affairs

    • Tenure: 1.9yrs

Board Members

  • Christi van Heek (62yo)

    Non-Executive Director

    • Tenure: 0.0yrs
  • Fred Schwarzer (66yo)

    Chairman of the Board

    • Tenure: 0.0yrs
  • Stephen Snowdy (49yo)

    CEO, President & Executive Director

    • Tenure: 6.2yrs
  • Zita Peach (54yo)

    Non-Executive Director

    • Tenure: 0.0yrs
  • Jean Franchi (53yo)

    Non-Executive Director

    • Tenure: 1.7yrs
  • Rosa Lee

    Executive Director of Manufacturing & Engineering

    • Tenure: 2.7yrs
  • Tom Dooley

    Non-Executive Director

    • Tenure: 2.3yrs

Company Information

Visioneering Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Visioneering Technologies, Inc.
  • Ticker: VTI
  • Exchange: ASX
  • Founded: 2008
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: AU$19.558m
  • Shares outstanding: 399.14m
  • Website: https://www.vtivision.com

Number of Employees


Location

  • Visioneering Technologies, Inc.
  • 10745 Westside Way
  • Suite 200
  • Alpharetta
  • Georgia
  • 30009
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VTIASX (Australian Securities Exchange)Class A Common StockAUAUDInvalid date
VTIASX (Australian Securities Exchange)YesCDI 1:1AUAUDMar 2017

Biography

Visioneering Technologies, Inc., a medical device company, engages in the design, manufacture, sale, and distribution of contact lenses in the United States. It offers NaturalVue, a contact lense for adult ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/25 10:44
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.